{"source":"polymarket","id":"503876","ticker":"fda-approves-cingulates-ctx-1301","slug":"fda-approves-cingulates-ctx-1301","title":"FDA approves Cingulate's Ctx-1301?","description":"As of market creation, the FDA's expected decision date for the specified application is May 31, 2026.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Cingulate's Ctx-1301 as a treatment for children and adults with attention-deficit/hyperactivity disorder (ADHD) by June 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nThis market will immediately resolve to \"No\" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to \"No\" immediately.\n\nIf the listed drug is approved before the end of the specified period, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.","image":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","icon":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","active":true,"closed":false,"start_date":"2026-05-20T19:59:42.703769Z","end_date":"2026-05-31T00:00:00Z","closed_time":null,"volume":9169.657215000001,"volume_24hr":1184.4438029999997,"volume_24h_change":null,"normalized_vol_24hr":15.923970222473145,"normalized_volume":18.898221969604492,"liquidity":1409.29761,"open_interest":3457.242049,"categories":["Science and Technology","Business"],"tags":[{"id":"1401","slug":"tech","label":"Tech"},{"id":"107","slug":"business","label":"Business"},{"id":"74","slug":"science","label":"Science"},{"id":"101489","slug":"fda","label":"FDA"},{"id":"101221","slug":"drug","label":"drug"},{"id":"104623","slug":"medicine","label":"Medicine"}],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"","top_outcome_probability":0.0245,"top_outcome_prob_24h_change":-0.34049999999999997,"top_outcome_volume_24h_change":1054.3603139999996,"updated_at":"2026-05-30T21:27:12.702468Z","fetched_at":"2026-05-30T21:27:12.702468Z","added_at":"2026-05-20T19:53:03.821066Z","url":"https://polymarket.com/event/fda-approves-cingulates-ctx-1301","chart_24h":[130.083489,130.083489,135.083489,403.738662,646.8763899999999,702.2463899999999,707.3473989999999,1209.5674989999998,1209.5674989999998,1209.5674989999998,1209.5674989999998,1209.5674989999998,1232.5574989999998,1249.6074989999997,1249.6074989999997,1249.6074989999997,1249.6074989999997,1249.6074989999997,1241.4908339999997,1241.4908339999997,1236.5152259999998,1284.5396179999998,1284.5396179999998,1284.5396179999998,1279.5396179999998,1281.9696179999999,1281.9696179999999,1276.99401,1236.99401,1236.99401,1236.99401,1190.4638029999996,1184.4438029999997,1184.4438029999997,1184.4438029999997],"markets":[{"source":"polymarket","id":"2307773","event_id":"503876","slug":"fda-approves-cingulates-ctx-1301","question":"FDA approves Cingulate's Ctx-1301?","group_item_title":null,"description":"As of market creation, the FDA's expected decision date for the specified application is May 31, 2026.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Cingulate's Ctx-1301 as a treatment for children and adults with attention-deficit/hyperactivity disorder (ADHD) by June 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nThis market will immediately resolve to \"No\" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to \"No\" immediately.\n\nIf the listed drug is approved before the end of the specified period, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.","image":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","icon":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","outcomes":["Yes","No"],"outcome_prices":[0.0245,0.9755],"probability":0.0245,"spread":0.009,"active":true,"closed":false,"start_date":"2026-05-20T19:48:10.099406Z","end_date":"2026-05-31T00:00:00Z","closed_time":null,"volume":9169.657215000001,"volume_24hr":1184.4438029999997,"prob_24h_change":-0.34049999999999997,"volume_24h_change":1054.3603139999996,"normalized_vol_24hr":16.54292869567871,"normalized_volume":24.422847747802734,"liquidity":1422.52447,"categories":["Science and Technology","Business"],"updated_at":"2026-05-30T21:28:34.166692Z","fetched_at":"2026-05-30T21:27:12.923671Z","added_at":"2026-05-20T19:53:03.834952Z","url":"https://polymarket.com/event/fda-approves-cingulates-ctx-1301/fda-approves-cingulates-ctx-1301","event_title":"FDA approves Cingulate's Ctx-1301?","chart_24h":[0.365,0.365,0.35,0.245,0.015,0.0105,0.015,0.011,0.08,0.0455,0.0355,0.04,0.015,0.014,0.0125,0.0555,0.0595,0.0575,0.0565,0.0715,0.051,0.045,0.045,0.038,0.0425,0.0205,0.024,0.02,0.02,0.0255,0.0245,0.0245]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/polymarket/503876","as_of":"2026-05-30T21:40:44.770724Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Polymarket): \"FDA approves Cingulate's Ctx-1301?\" — top market at 2% probability across 1 outcome","source_url":null}}